PATENT CLAIM ANALYSIS

Application Number: 15896423
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "199100"]

Abstract:
Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin α4β1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.

Claim (Index 14):
The method of  claim 1  wherein said VLA4+ NPC is delivered in an amount sufficient to improve one or more parameters selected from neurological pathology, survival, brain inflammation, brain neurodegeneration, GCase activity, GCase substrate level, mitochondrial function, neurotropic factor expression, or combinations thereof.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 88.0
- Lexical Diversity: 1.36842
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15399165', '14494065', '14127546', '14884503', '12384446']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7298443825971428
- 35 USC 102 Novelty (BERT): 0.514732383454393
- Combined Prediction Score: 0.7083331826828678
- Mean Citation Score: 221.888356
- Max Citation Score: 252.54108
- Similarity Product: 148.96095176071643

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test